LIXTE Names Healthcare Veteran Sidney Braun to Lead European Proton Therapy Subsidiary
Event summary
- Sidney Braun appointed CEO of LIXTE's Liora Technologies Europe Ltd. subsidiary on February 18, 2026.
- Braun brings over 20 years of healthcare industry experience, including roles in North America, Europe, and Israel.
- Braun facilitated LIXTE’s acquisition of Liora’s assets from Orbit Capital in November 2025.
- Liora’s LiGHT System is a proprietary electronically controlled proton therapy technology for cancer treatment.
The big picture
LIXTE’s appointment of Sidney Braun as CEO of its European subsidiary underscores its strategic push to commercialize advanced cancer treatment technologies. The move aligns with broader industry trends toward precision medicine and recurring revenue models in healthcare. Braun’s extensive experience in building healthcare networks and his role in facilitating LIXTE’s acquisition of Liora’s assets suggest a focused effort to scale the LiGHT System’s market reach.
What we're watching
- Technology Scaling
- How quickly Liora’s LiGHT System can be scaled and integrated into existing cancer treatment protocols.
- Recurring Revenue
- Whether LIXTE can successfully transition to a recurring revenue model through the LiGHT System.
- Leadership Impact
- The pace at which Sidney Braun can drive operational and strategic advancements at Liora.
Related topics